NEW YORK (GenomeWeb News) – Cancer care firm N-of-One today announced a deal with Foundation Medicine to translate sequencing data into clinically relevant information.
Under the terms of the agreement, Foundation will identify potential biomarkers using its sequencing and analytic capabilities on patient tumor samples. N-of-One will then use its PrecisionWorks platform to translate data from Foundation to link molecular changes with current information about relevant target therapies and clinical trials that may be used to guide treatment.
Financial and other terms of the deal were not disclosed.
"This collaboration represents another important step toward transforming next-generation sequencing into a decision-making tool that empowers oncologists to act rapidly and decisively in providing precision treatment strategies for their patients," Jennifer Levin Carter, founder and president of N-of-One, said in a statement.
Based in Waltham, Mass., N-of-One develops "roadmaps" to drive "highly informed clinical decision-making by linking data about the molecular variations in each patient's cancer cells with leading-edge knowledge, diagnostics, treatments, and technologies relevant to the tumor type," it said.
According to the firm, PrecisionWorks is a knowledge integration platform that integrates a molecular knowledge database, biomedical informatics, advanced knowledge synthesis capabilities, and logistics management systems.
Foundation Medicine is a molecular information firm based in Cambridge, Mass., and provides reports to oncologists to help them determine appropriate treatments for individual patients.